Jack Kaye Sells uniQure N.V. Shares Under Planned Sale
Insider Jack Kaye sold 5,295 shares of uniQure N.V. for $225,408.15 on June 17, 2026.
Key Points
- Jack Kaye sold 5,295 shares of uniQure N.V. (QURE) for $225,408.15 under a planned sale on June 17, 2026.
- uniQure N.V. trades on NasdaqGS with a market cap of about $2.92 billion and a 52-week range of $8.73 to $71.50.
- Analysts recently set new price targets for uniQure, with Barclays upgrading to a 'buy' and setting a $65 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, Jack Kaye, an insider at uniQure N.V., sold 5,295 shares of the company at an average price of $42.57 each. This planned sale brought in a total of $225,408.15.
Insider Buying and Selling at uniQure N.V.
Jack Kaye's transaction on June 17 was part of a planned sale, involving 5,295 shares at a price of $42.57 per share. Additionally, on June 15, Madhavan Balachandran sold 10,000 shares, while Jeannette Potts, the Chief Legal Officer, sold 5,237 shares at $27.67 each.
Other Institutional Activity in uniQure N.V.
Several institutional investors have recently adjusted their stakes in uniQure. AVORO Capital Advisors LLC reduced its holdings by 190,405 shares, bringing its total to 5,959,595 shares valued at approximately $97.4 million. Meanwhile, Aberdeen Group PLC increased its position by 1,627,746 shares, ending with 5,306,386 shares worth about $86.8 million. Two Sigma Investments, LP also boosted its holdings significantly by 1,224,587 shares to a total of 2,675,871 shares, valued at $43.8 million.
uniQure N.V. Stock Down 6.1%
As of Monday, shares of NasdaqGS:QURE traded near $46.37. The company, with a market cap of approximately $2.92 billion, operates in the biotechnology sector. It has a 52-week low of $8.73 and a high of $71.50. The stock's 50-day moving average is $24.13, and its 200-day moving average is $27.53. uniQure has a high current ratio of 10.40, reflecting strong liquidity, but its debt-to-equity ratio is elevated at 365.37.
$QURE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 18, 2026, Barclays upgraded uniQure to a 'buy' with a price target of $65. Goldman Sachs maintained a 'hold' rating with a target of $46, while Leerink Partners and RBC Capital both reaffirmed their 'buy' ratings, setting targets of $70 and $65, respectively. Overall, the consensus among 11 analysts is a 'strong buy', with a mean target price of $58.75.
About uniQure N.V.
uniQure N.V., headquartered in Amsterdam, Netherlands, focuses on developing gene therapies for rare and serious diseases. Its flagship product, HEMGENIX, helps hemophilia B patients manage bleeding. The company is also advancing AMT-130 for Huntington's disease and other gene therapy candidates for conditions like epilepsy and amyotrophic lateral sclerosis. Led by CEO Matthew Craig Kapusta, uniQure employs 221 people.
Bottom Line
Jack Kaye's planned sale of uniQure shares is a notable insider activity, but it doesn't necessarily indicate any negative sentiment about the company. uniQure continues to be a significant player in biotechnology, with promising therapies in its pipeline. Investors often track insider transactions for potential insights, while also considering analyst opinions and market positioning.
Get uniQure N.V. alerts
New 13F filings, insider trades, and analyst moves on $QURE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.